liveBook · Manning

Adversarial validation

As explained in Build AI Drug Discovery Pipelines

Adversarial validation trains a classifier to distinguish examples from two data partitions in order to detect distribution differences between them.

Adversarial validation tests whether a classifier can distinguish molecular fingerprints from the training and test partitions. Easy discrimination signals different chemical-space distributions and possible test-set extrapolation beyond the model’s applicability domain. section 5.3.2

Apply it as a practical distribution-shift check:

  • Label training examples as 0 and test examples as 1, concatenate them, shuffle, and split the combined data. section 5.3.2
  • Train a binary classifier on molecular fingerprints and evaluate its ability to recover the original partition labels. section 5.3.2
  • Interpret low performance as structural similarity and high performance as distinguishable chemical distributions. section 5.3.2

Random-forest applicability-domain check

A Random Forest trained for adversarial validation produced PR AUC 0.504, indicating that the original training and test fingerprints were difficult to distinguish in this assessment.

How Build AI Drug Discovery Pipelines covers it

How deep it goes
Explains the workflow, interpretation, and executable Random Forest implementation, but does not develop underlying distribution-shift theory.
Examples
Uses labeled training and test fingerprints, a binary Random Forest, and an adversarial-validation PR AUC of 0.504.
What it assumes
Assumes training and test partitions, molecular fingerprints, binary classifiers, and PR AUC evaluation.
What you can do after
Diagnose chemical-distribution differences that may place test molecules outside a model’s applicability domain.
How it connects
Connects applicability domains, molecular fingerprints, Random Forests, chemical space, and precision-recall AUC.

Also explained in

Compare how 2 books explain adversarial validation →

Related concepts

This explainer was generated by Manning's knowledge graph from the text of Build AI Drug Discovery Pipelines. The section links point to the parts of the book it draws on.